Financial News
Articles published by Incyte
![](https://mms.businesswire.com/media/20220215005154/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
February 15, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220203005010/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
February 03, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220125006021/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Provides Update on Parsaclisib and MCLA-145
January 25, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20220118005069/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
January 18, 2022
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211214006227/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20211214005005/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conferences
December 14, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211211005013/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20211211005002/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20211109005066/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
November 09, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211104005202/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
More than 35 Abstracts from Incyte’s Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition
November 04, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211102005601/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 02, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211101005607/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20211101005269/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Announces Acceptance of NDA for Parsaclisib for Three Types of Relapsed or Refractory Non-Hodgkin Lymphomas
November 01, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211028005620/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Announces the Validation of the European Marketing Authorization Application for Ruxolitinib Cream in Vitiligo
October 28, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211013005111/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Third Quarter Financial Results
October 13, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20211002005006/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Announces Full Results From Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
October 02, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210928006095/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Names New Member to Its Board of Directors
September 28, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210922005863/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
September 22, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210921006072/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20210913005816/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20210826005704/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20210817005012/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Present at Upcoming Investor Conference
August 17, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210816005733/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
August 16, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210803005426/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 03, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210715005037/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Incyte to Report Second Quarter Financial Results
July 15, 2021
From Incyte
Via Business Wire
Tickers
INCY
![](https://mms.businesswire.com/media/20210714005868/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20210625005231/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20210624005968/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
![](https://mms.businesswire.com/media/20210612005013/en/1078784/5/Incyte_Color_Logo_JPEG_%282_Color_Positive%29.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.